{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-171026","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2022-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.812944+00:00","generated_at":"2026-06-25T03:12:40.654871+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Fulcrum Therapeutics reports 2022 annual meeting vote results","bullets":["Elected Kate Haviland, Katina Dorton, Robert Gould as Class III directors for three-year term ending 2025.","Director vote results: Haviland 25,135,506 for / 5,600,007 withheld; Dorton 27,146,569 for / 3,588,944 withheld; Gould 26,665,833 for / 4,069,680 withheld.","Ratified Ernst & Young LLP as independent auditor for FY2022: 34,538,061 for, 20,325 against, 10,946 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-171026","json":"https://secwatch.observer/filing/0001193125-22-171026.json","markdown":"https://secwatch.observer/filing/0001193125-22-171026.md","text":"https://secwatch.observer/filing/0001193125-22-171026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522171026/0001193125-22-171026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312522171026/d334925d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:12:40.654871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}